Do you have any ideas or suggestions about information that you would find helpful to see on this website, please contact one of our Project Leaders:

Marie-Hélène Masse
Julie Ménard
Sheila Sprague

Thanks to all Participating Centers and collaborators for engaging in this research program!

Thanks to the CCCTG for endorsing this research project.

TOP 10 Reasons to participate in LOVIT and LOVIT-COVID

  1. In the context of increasing off-label use of vitamin C for sepsis and ongoing trials of vitamin C bundled with other pharmacological interventions, the LOVIT and LOVIT-COVID Trials will constitute a trustworthy assessment of the effect of vitamin C alone on patient-important outcomes.
  1. The eligibility criteria are simple and pragmatic: all patients admitted to the ICU with proven or suspected infection as the main who are receiving vasopressor therapy.
  1. The randomization system is accessible 24/7 on Internet and bags can be prepared in advance to allow off-business hours randomization.
  1. The intervention is easy to implement: participants receive vitamin C or placebo every 6 hours for 96 hours.
  1. The safety profile for vitamin C is remarkably favourable.
  1. All co-interventions are at the discretion of the treating team.
  1. Blood and urine samples are collected only on days 1, 3, and 7 and will coincide with routine urine and blood testing.
  1. Study participants will be involved by being asked about their quality of life at 6 months.
  1. If vitamin C is proven to be effective, it is likely to be used worldwide and improve outcomes globally, given low cost and ease of administration.
  1. The LOVIT and LOVIT-COVID Coordinating Centre team is highly supportive and responsive to your needs and suggestions!